Australia's Lumos Diagnostics gains as US FDA grants waiver for FebriDx

Shares of Australia's Lumos Diagnostics LDX.AX gain as much as 7.6% to A$0.285, their highest point since March 19

The diagnostic firm says U.S. FDA grants Clinical Laboratory Improvement Amendments waiver for FebriDx, a point-of-care test for respiratory infections

LDX also announced share purchase plan to raise about A$2 million ($1.38 million) at A$0.225 per share

Around 10.9 million shares change hands, nearly 3.8x of 30-day average

LDX stock down 1.8%, YTD

($1 = 1.4529 Australian dollars)